<?xml version="1.0" encoding="UTF-8"?>
<p>Two years later, Zhao et al. [
 <xref rid="B66-ijms-22-00634" ref-type="bibr">66</xref>] published the results of a pilot randomized clinical trial with 48 breast cancer patients with cancer-related fatigue undergoing endocrine therapy receiving 1000 mg of 
 <italic>G</italic>. 
 <italic>lucidum</italic> spore powder three times a day for 4 weeks. The survey parameters were obtained using the Functional Assessment of Cancer Therapy: Fatigue (FACT-F), Hospital Anxiety and Depression Scale (HADS), and European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire C30 (EORTC-QLQ-C30) questionnaires. The concentrations of TNF-α and IL-6 and liver–kidney functions were assessed both before and after treatment.
</p>
